Clinical trial • Not applicable • Immunology
MV130-SLG-039 for Healthy adult volunteers
Not applicable trial of MV130-SLG-039 for Healthy adult volunteers. 48 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Healthy adult volunteers
- Trial Stage
- Not applicable
- Drug Modality
- Vaccine
Key dates
- Initial CTIS Submission Date
- 14-10-2024
- First CTIS Authorization Date
- 30-10-2024
Trial design
Not applicable trial across 1 site in Spain.
- Target Sample Size
- 48
Eligibility
Recruits 48 No vulnerable populations selected..
- Vulnerable Population
- No vulnerable populations selected.
Recruitment
- Planned Sample Size
- 48
- Recruitment Window Months
- 27
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 48
Spain
- Earliest CTIS Part Ii Submission Date
- 12-08-2024
- Latest Decision Or Authorization Date
- 30-10-2024
- Processing Time Days
- 79
- Number Of Sites
- 1
- Number Of Participants
- 48
Sites
- Site Name
- Hospital Clinico San Carlos
- Department Name
- Immunology
- Principal Investigator Name
- Silvia Sánchez-Ramón
- Principal Investigator Email
- ssramon@salud.madrid.org
- Contact Person Name
- Silvia Sánchez-Ramón
- Contact Person Email
- ssramon@salud.madrid.org
Sponsor
Primary sponsor
- Full Name
- Inmunotek S.L.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- MV130-SLG-039
- Modality
- Vaccine
- Routes Of Administration
- Sublingual
- Route
- Sublingual
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis